# A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

> **NCT04672369** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 42 (actual)

## Conditions studied

- Advanced Lung Cancer

## Interventions

- **BIOLOGICAL:** IBI939
- **BIOLOGICAL:** Sintilimab

## Key facts

- **NCT ID:** NCT04672369
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-06
- **Primary completion:** 2023-01-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04672369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04672369, "A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04672369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*